Literature DB >> 11435602

E box-dependent activation of telomerase by human papillomavirus type 16 E6 does not require induction of c-myc.

L Gewin1, D A Galloway.   

Abstract

Human papillomavirus type 16 (HPV-16) E6 activates telomerase specifically in epithelial cells. The oncogene c-myc has also been shown to activate telomerase in several cell types. Here we show that while both HPV-16 E6 and c-myc require intact E boxes to transactivate the hTERT promoter, E6 does not induce hTERT transcription simply by inducing expression of c-myc. Moreover, hTERT transactivation by HPV-16 E6 correlates with its ability to bind the cellular E6-associated protein (E6AP), suggesting that E6 and E6AP may target a regulator of hTERT expression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11435602      PMCID: PMC114450          DOI: 10.1128/JVI.75.15.7198-7201.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Adenovirus-mediated p53 gene transduction inhibits telomerase activity independent of its effects on cell cycle arrest and apoptosis in human pancreatic cancer cells.

Authors:  M Kusumoto; T Ogawa; K Mizumoto; H Ueno; H Niiyama; N Sato; M Nakamura; M Tanaka
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

2.  Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins.

Authors:  J M Huibregtse; M Scheffner; P M Howley
Journal:  Mol Cell Biol       Date:  1993-08       Impact factor: 4.272

3.  Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells.

Authors:  Y Liu; J J Chen; Q Gao; S Dalal; Y Hong; C P Mansur; V Band; E J Androphy
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

4.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.

Authors:  M Scheffner; B A Werness; J M Huibregtse; A J Levine; P M Howley
Journal:  Cell       Date:  1990-12-21       Impact factor: 41.582

5.  The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product.

Authors:  N Dyson; P M Howley; K Münger; E Harlow
Journal:  Science       Date:  1989-02-17       Impact factor: 47.728

6.  Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein.

Authors:  T Veldman; I Horikawa; J C Barrett; R Schlegel
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

7.  The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells.

Authors:  C L Halbert; G W Demers; D A Galloway
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

8.  Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation.

Authors:  T Crook; J A Tidy; K H Vousden
Journal:  Cell       Date:  1991-11-01       Impact factor: 41.582

9.  A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18.

Authors:  J M Huibregtse; M Scheffner; P M Howley
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

10.  The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein.

Authors:  J A Mietz; T Unger; J M Huibregtse; P M Howley
Journal:  EMBO J       Date:  1992-12       Impact factor: 11.598

View more
  74 in total

1.  Human papillomavirus type 31 E5 protein supports cell cycle progression and activates late viral functions upon epithelial differentiation.

Authors:  Frauke Fehrmann; David J Klumpp; Laimonis A Laimins
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

2.  Degradation of p53, not telomerase activation, by E6 is required for bypass of crisis and immortalization by human papillomavirus type 16 E6/E7.

Authors:  H R McMurray; D J McCance
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

Review 3.  Mechanisms of human papillomavirus-induced oncogenesis.

Authors:  Karl Münger; Amy Baldwin; Kirsten M Edwards; Hiroyuki Hayakawa; Christine L Nguyen; Michael Owens; Miranda Grace; Kyungwon Huh
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

Review 4.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

5.  Immortalization of human urothelial cells by human papillomavirus type 16 E6 and E7 genes in a defined serum-free system.

Authors:  N Carmean; J W Kosman; E M Leaf; A E Hudson; K E Opheim; J A Bassuk
Journal:  Cell Prolif       Date:  2007-04       Impact factor: 6.831

Review 6.  Papillomavirus E6 oncoproteins.

Authors:  Scott B Vande Pol; Aloysius J Klingelhutz
Journal:  Virology       Date:  2013-05-24       Impact factor: 3.616

7.  Differential in vitro immortalization capacity of eleven (probable) [corrected] high-risk human papillomavirus types.

Authors:  Denise M Schütze; Peter J F Snijders; Leontien Bosch; Duco Kramer; Chris J L M Meijer; Renske D M Steenbergen
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

8.  Cell-restricted immortalization by human papillomavirus correlates with telomerase activation and engagement of the hTERT promoter by Myc.

Authors:  Xuefeng Liu; Aleksandra Dakic; Renxiang Chen; Gary L Disbrow; Yiyu Zhang; Yuhai Dai; Richard Schlegel
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

9.  HPV E7 contributes to the telomerase activity of immortalized and tumorigenic cells and augments E6-induced hTERT promoter function.

Authors:  Xuefeng Liu; Jeffrey Roberts; Aleksandra Dakic; Yiyu Zhang; Richard Schlegel
Journal:  Virology       Date:  2008-03-26       Impact factor: 3.616

Review 10.  Human telomerase and its regulation.

Authors:  Yu-Sheng Cong; Woodring E Wright; Jerry W Shay
Journal:  Microbiol Mol Biol Rev       Date:  2002-09       Impact factor: 11.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.